Members of the OzNose project were recently successful in being awarded a competitive National Health and Medical Research Development Grant of $401,708 to develop a device and formulation that targets chronic sinus infection.
Chronic sinus infection (CSI) is prevalent and results in severe discomfort and pain for many Australians; yet amazingly, has no specific cure or effective treatment. This multi-disciplinary research team and an Australian health and medical research company, (AFT Pharmaceuticals) have partnered to develop a novel device that specifically targets the sinuses and a formulation capable for simultaneously removing mucus, dispersing biofilms and killing bacteria in the nasal cavities.
The research team includes Woolcock and University of Sydney based Associate Professors Paul Young, Daniela Traini and Greg King, Professor Dale Bailey from University of Sydney Central Clinical School, Dr Ramin Rohanizadeh, from the University of Sydney School of Pharmacy and Associate Professor Cynthia Whitchurch from the ithree institute at the University of Technology Sydney.
You can learn more about the RespiTech team at the Woolcock Institute of Medical Research here